168 related articles for article (PubMed ID: 9446255)
1. [SDZ PSC 833: a novel modulator of MDR].
Covelli A
Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
3. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
4. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
5. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D
Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277
[TBL] [Abstract][Full Text] [Related]
7. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Giaccone G; Linn SC; Welink J; Catimel G; Stieltjes H; van der Vijgh WJ; Eeltink C; Vermorken JB; Pinedo HM
Clin Cancer Res; 1997 Nov; 3(11):2005-15. PubMed ID: 9815591
[TBL] [Abstract][Full Text] [Related]
8. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
[TBL] [Abstract][Full Text] [Related]
10. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells.
Cabot MC; Giuliano AE; Han TY; Liu YY
Cancer Res; 1999 Feb; 59(4):880-5. PubMed ID: 10029079
[TBL] [Abstract][Full Text] [Related]
11. The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833.
Ehrlich PH; Moustafa ZA; Archinal-Mattheis AE; Newman MJ; Bair KW; Cohen D
Anticancer Res; 1997; 17(1A):129-33. PubMed ID: 9066642
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic approaches to reversing multidrug resistance.
Sikic BI
Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
[TBL] [Abstract][Full Text] [Related]
13. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
15. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
Uchiyama-Kokubu N; Watanabe T; Nakajima M
Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963
[TBL] [Abstract][Full Text] [Related]
16. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.
Keller RP; Altermatt HJ; Donatsch P; Zihlmann H; Laissue JA; Hiestand PC
Int J Cancer; 1992 May; 51(3):433-8. PubMed ID: 1534319
[TBL] [Abstract][Full Text] [Related]
18. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein.
Goulding CW; Giuliano AE; Cabot MC
Cancer Lett; 2000 Feb; 149(1-2):143-51. PubMed ID: 10737718
[TBL] [Abstract][Full Text] [Related]
19. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
[TBL] [Abstract][Full Text] [Related]
20. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.
Jachez B; Nordmann R; Loor F
J Natl Cancer Inst; 1993 Mar; 85(6):478-83. PubMed ID: 8095304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]